SF3B1 and myelodysplastic syndrome: These markers not only provide key prognostic information but increasingly determine eligibility for targeted agents (like eprenetapopt for TP53-mutant MDS; luspatercept for SF3B1-mutant MDS) and guide rational therapeutic combinations.